Company Overview
China’s leading biopharmaceutical company

Founded in 2005, Dragon Boat Pharmaceutical is a high-tech enterprise committed to the research and development of biologics. We focus on the therapeutic area for gastrointestinal cancer and are dedicated to bringing novel drugs for treating oncology and autoimmune disease to global patients. The company was wholly owned by Guilin Sanjin (002275) since 2013.

Adhering to the concept of independent innovation, we established a drug R&D center in Zhangjiang high-tech park, occupying 5,000 square meters, covering early discovery, preclinical research, IND, clinical research, BLA and manufacturing. Our pipeline has 9 biologics candidates, covering multiple modalities and multiple immune targets. As of today, 4 of them entered the clinical development stage. With insistent investment to R&D and excellent drug discovery capability, Dragon boat Pharmaceutical became a leading innovative biotech company in China.

Corporate Culture

Innovation for a healthier world

  • Vision Vision
    Vision
    Become the world's leading
    biopharmaceutical company
  • Mission Mission
    Mission
    Dedicated to better biologics
    for the world
  • Value Value
    Value
    Patients first     Quality first
    Efficacy first     Team first
  • Strategy Strategy
    Strategy
    Developing biologic drugs that met the unmet
    medical needs in GI cancer therapeutic area
Management Team
Yingfeng Huang
Yingfeng Huang
President
Yingfeng Huang
President

Seasoned manager with over 15 years’ experience in biologics R&D. He led dozens of preclinical and clinical programs of therapeutic antibodies in Fudan Zhang Jiang and Dragon Boat. He is also expert in pharmacology and process development. Huang holds a P

Zhe Shao
Zhe Shao
VP, Preclinical R&D
Zhe Shao
VP, Preclinical R&D

With over 10-years’ experience in R&D and quality management of biologics, she served as a research scientist at NUS and A*Star Singapore before joining Dragon Boat Biopharmaceutical. She is specializing in analytical testing and quality management. Shao

Huilan Ou
Huilan Ou
VP, Regulatory Affairs
Huilan Ou
VP, Regulatory Affairs

Regulatory expert with over 16 years’ experience in regulatory affairs for biosimilar and new drug development. She was the former leader of Regulatory Affairs at Henlius and successfully submitted and maintained major regulatory applications to NMPA, inc

Zheng Ruan
Zheng Ruan
VP, Finance
Zheng Ruan
VP, Finance

Having extensive experience in financing and investing in the biotech and pharmaceutical industry, Ruan was once the long-term director of fund-raising & investment at Guilin Sanjin. Ruan graduated from Tongji Medical College of Huazhong University of Sci

Award and Recognition

Dragon Boat is proud to be recognized by the government and some of the most influential organizations.

National High-tech Enterprise Designation
National High-tech Enterprise Designation
Pudong New Area R&D Institutions Designation
Pudong New Area R&D Institutions Designation
Independent Innovation & Professional Technology SMEs Nomination
Independent Innovation & Professional Technology SMEs Nomination
Member Award of Shanghai Biomedical Industry Association
Member Award of Shanghai Biomedical Industry Association
2021 Annual Award for The Most Promising Company for Innovative Biologics
2021 Annual Award for The Most Promising Company for Innovative Biologics
Journey of Dragon Boat
2012
2012

An in-house developed biosimilar of etanercept was licensed to Merck Serono (EU),
which has exclusive rights for developing, manufacturing, and commercializing the
candidate.

2013

Fully acquired as a subsidiary company of TCM producer, Guilin Sanjin Pharmaceutical, and changed company name to Dragon Boat Biopharmaceuticals.

2013
2016
2016

Received first NMPA IND approval for the lead candidates BC001 in China.

2021

China’s first anti-CSF-1R antibody (BC006) entered clinical-stage

2021
2005
2005

Founded in Shanghai under the name of Dragonfly Sciences as a contract research
organization.

2008

Transformed into a biotech company and devoted to contributing to human health by
developing novel antibody drugs.

2008